1. Home
  2. MPWR vs BIIB Comparison

MPWR vs BIIB Comparison

Compare MPWR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monolithic Power Systems Inc.

MPWR

Monolithic Power Systems Inc.

HOLD

Current Price

$1,069.49

Market Cap

52.9B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$187.65

Market Cap

27.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPWR
BIIB
Founded
1997
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.9B
27.1B
IPO Year
2004
1996

Fundamental Metrics

Financial Performance
Metric
MPWR
BIIB
Price
$1,069.49
$187.65
Analyst Decision
Strong Buy
Buy
Analyst Count
14
27
Target Price
$1,122.93
$195.00
AVG Volume (30 Days)
442.0K
721.8K
Earning Date
04-30-2026
04-30-2026
Dividend Yield
0.76%
N/A
EPS Growth
N/A
N/A
EPS
12.86
8.79
Revenue
$333,067,000.00
$9,890,600,000.00
Revenue This Year
$23.74
N/A
Revenue Next Year
$17.55
N/A
P/E Ratio
$82.35
$21.75
Revenue Growth
17.89
2.22
52 Week Low
$438.86
$110.04
52 Week High
$1,256.22
$202.41

Technical Indicators

Market Signals
Indicator
MPWR
BIIB
Relative Strength Index (RSI) 46.96 51.01
Support Level $899.99 $170.99
Resistance Level $1,123.38 $191.60
Average True Range (ATR) 36.52 4.17
MACD 1.46 0.34
Stochastic Oscillator 46.65 52.17

Price Performance

Historical Comparison
MPWR
BIIB

About MPWR Monolithic Power Systems Inc.

Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: